Oct 02 2026 11:42 PM EST

Agilon Health Shares Rally on Profit Turn and Raised FY 2026 Outlook

Agilon Health (NYSE: AGL) reported its first quarterly GAAP profit in more than a decade and lifted its full‑year 2026 outlook, prompting the stock to climb more than 260% since the start of 2026. The earnings beat, improved margins and a favorable Medicare Advantage payment environment have led investors to reassess the company’s growth trajectory and valuation.

In the second quarter of 2026, revenue reached $1.49 billion, up roughly 7 % year‑over‑year and beating consensus estimates by about 3 %. GAAP earnings per share came in at $1.04 versus a consensus of $0.08. Net income turned positive at $17.96 million, a swing from a $104.37 million loss a year earlier. Adjusted EBITDA improved to $70 million, reversing a $83 million negative result in Q2 2025. The company also raised its FY 2026 revenue guidance to a range of $5.68 billion‑$5.81 billion and its medical‑margin target to $350 million‑$400 million.

Quarterly Profit Marks Operational Turnaround

The Q1 2026 results, released in early May, already showed a net income of $49 million and a medical margin of $149 million, despite a 7 % revenue decline to $1.42 billion. Adjusted EBITDA rose 162 % YoY to $54 million. Management attributed the improvement to disciplined cost control—operating expenses were trimmed by roughly $30 million in 2026—and to higher‑margin ACO REACH contributions, which added $27 million to adjusted EBITDA in Q1 2026 versus $20 million a year earlier.

Guidance Upgrade Reflects Strong Medicare Advantage Tailwinds

CMS finalized the CY 2026 Medicare Advantage payment policy in early 2026, introducing a 5.06 % rate increase—equating to more than $25 billion in additional payments across the market. Agilon’s MA‑focused capitation model stands to benefit directly, a factor highlighted in the company’s raised guidance. The company also cited a new full‑risk contract signed in Q1 2026 and expanded physician‑partner networks now exceeding 3,000 primary‑care physicians, which support higher risk‑adjusted savings.

Capital Structure and Liquidity Remain Comfortable

Cash and equivalents stood at $257 million as of June 30 2026, with total debt of $32 million. An additional $83 million is linked to unconsolidated ACO entities, providing further liquidity for the REACH model. The balance‑sheet strength supports ongoing expansion without immediate financing pressure.

Market Valuation and Analyst Sentiment

Following the Q2 earnings release, the stock rose roughly 2.6 % to $110.51. After the earlier Q1 surprise, the share price surged 126.85 % to about $60.66 in pre‑market trading. As of October 2 2026, the shares trade near $69.54, reflecting a 30‑day return of +265.62 % and a YTD gain of +312.95 %. Consensus ratings remain “Hold,” with analysts such as Citigroup and Robert W. Baird upgrading price targets to $115‑$116, while Jefferies and Deutsche Bank have moved to “Buy” with targets around $48‑$49. The average 12‑month target sits near $75‑$76.

Risks and Uncertainties

Key risks include continued NYSE delisting pressure after the share price fell below $1.00 in late 2025, prompting a 1‑for‑25 reverse split in March 2026. Regulatory scrutiny over the corporate practice of medicine doctrine and potential changes to Medicare Advantage reimbursement could also affect profitability. Additionally, the company remains dependent on expanding its physician‑partner network and securing new full‑risk contracts; any slowdown in geography or payer development would constrain revenue growth.